Article
Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemia.
PloS one - 1 Jan 2014
Letz Saskia, Haag Christine, Schulze Egbert, Frank-Raue Karin, Raue Friedhelm, Hofner Benjamin, Mayr Bernhard, Schöfl Christof
Abstract excerpt
INTRODUCTION: Activating calcium sensing receptor (CaSR) mutations cause autosomal dominant hypocalcemia (ADH) characterized by low serum calcium, inappropriately low PTH and relative hypercalciuria. Four activating CaSR mutations cause additional renal wasting of sodium, chloride and other salts, a condition called Bartter syndrome (BS) type 5. Until today there is no specific medical treatment for BS type 5 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.